1. An FDA/CDER perspective on nonclinical testing strategies: classical toxicology approaches and new approach methodologies (NAMs);Avila;Regul Toxicol Pharmacol,2020
2. Controlled Terminology, SEND/CDISC, National Institute of Health. https://www.cdisc.org/standards/terminology/controlled-terminology. (Accessed January 2021).
3. Guidance for industry S7A safety pharmacology studies for human pharmaceuticals,2001
4. Guidance for industry S8 immunotoxicity studies for human pharmaceuticals,2006
5. International Harmonization of Nomenclature and Diagnostic Criteria (INHAND). www.toxpath.org/inhand.asp. (Accessed January 2021).